Effector B cells in cardiac allograft vasculopathy

Area of Science:

• Immunology
• Transplantation Immunology
• Cardiovascular Research

Background:

• B cells are increasingly recognized for their role in solid organ rejection.
• Cardiac allograft vasculopathy (CAV) is a chronic rejection form following heart transplantation.
• B cells can exhibit both regulatory and effector immune functions.

Purpose of the Study:

• To review the current understanding of effector B cells in CAV.
• To highlight recent findings on B cell infiltrates and their characteristics in CAV.
• To discuss the potential therapeutic implications of targeting B cells in CAV.

Main Methods:

• Review of independent studies on B cell infiltrates in CAV.
• Analysis of B cell populations (CD20+, CD27+, CD138+) in cardiac allografts.
• Characterization of B cell clones from explanted human cardiac grafts.
• Evaluation of B cell functions in situ, including antigen presentation and cytokine production.

Main Results:

• B cells, including memory B cells and plasma cells, are abundant in CAV infiltrates, often forming tertiary lymphoid organs.
• B cell infiltrates are typically found without donor-specific antibodies, suggesting distinct pathogenic mechanisms.
• Isolated B cell clones are often polyreactive and B1-like, functioning as antigen-presenting cells.
• Effector functions include local antibody secretion, pro-inflammatory cytokine release, and promotion of fibrosis.

Conclusions:

• Evidence from human and animal studies supports a significant role for effector B cells in CAV pathophysiology.
• Targeting B cells represents a promising therapeutic strategy for managing CAV.
• Further research into B cell mechanisms in CAV is warranted to optimize therapeutic interventions.